bill. But to many others in the United States and elsewhere the idea of a NICE-like body is unfathomable. Former Republican vicepresidential candidate Sarah Palin summed up the feelings of many when she warned in a statement in August this year that health-care rationing would lead to a "death panel" for patients in which "bureaucrats can decide … whether they are worthy of health care".
In the United Kingdom, bureaucrats and health-care rationing are a way of life. What is sometimes lost in the midst of the debate is the research itself, which in the case of NICE involves synthesizing evidence and building models that attempt to assign hard values to the quality and cost of each additional month by which a treatment extends life. The researchers who do this work, however, are well aware that their results can have profound effects for the population. "You are obviously always very aware that this is a very important piece of work," says Thompson Coon. "It is not going to sit on a dusty shelf for no one to read. On the other hand, you have to keep it evidence-based. "
Health arbiter
NICE was born in 1999 amid concerns that patients in Britain's National Health Service (NHS), which provides the vast majority of the nation's health care, were not being given the most effective treatments. Established by the Labour government, its purpose is to make sure that the NHS spends its budget -raised by taxation -wisely, using a transparent decision-making process that is based on the best evidence available.
For many conditions, there is scant evidence to show doctors and patients which of two or more medical alternatives -be it treatments, diagnostic techniques or prevention methods -is likely to be more successful. Comparativeeffectiveness research aims to find out which one is best, either by pulling together existing research or by commissioning new studies.
On its own the research is relatively uncontroversial. Where NICE gets into hot water is when money is added to the mix. Even if a treatment is more effective clinically than a rival, NICE committee members can decide that the gain in health that it bestows is not worth the additional cost. NICE issues guidance on issues ranging from medical procedures to public health, and the ones that tend to be most controversial are its 'technology appraisals' , which tell the NHS under what conditions treatments -particularly new ones -must be offered.
The decision over bevacizumab, sorafenib, The team initially identified 888 potentially relevant studies through electronic searches of various databases. Many of these were excluded for being reviews, reanalyses of the same data or studies that did not meet the researchers' experimental standards, such as being placebo controlled. This left them with 13 relevant papers from 8 clinical studies. For this study "there was actually quite a reasonable amount of evidence", says Thompson Coon. "Because they're new drugs there isn't always that much data available. If you were doing a systematic review of a more established technology you' d probably expect to fi nd more. "
In a number of patient groups and disease scenarios, the research team found that the new drugs were better than existing treatments. For example, one of the studies 2 they included showed that people with untreated metastatic renal-cell carcinoma who were given bevacizumab and interferon-α lived without their cancer progressing for just 10.2 months, compared with 5.4 months for those given a placebo and interferon-α.
But a drug that extends life is not much good if the individuals who take it spend that time in crippling pain. So the trick for the assessment team is to assign a somewhat abstract quality of life value -called a 'utility value' -to these additional months or years. Typically, perfect health scores a one. Dead is zero. Putting values in between is the complicated bit.
One way to measure quality of life is using a 'time trade-off ' method. Individuals are asked: if you were going to be in a particular health state for ten years, how many years of life would you be prepared to forfeit to be in perfect health? To avoid constant pain, for example, someone might be prepared to give up eight years of life for two in perfect health: this state would be rated 0.2. To avoid a more minor condition a person might only be prepared to forfeit six months, rating 0.95 on the scale. "What's very important is the measure of quality must be based on actual choices that people are willing to make, " says Karl Claxton, a health economist at the University of York, UK, who has served on various NICE appraisal committees.
Ideally, the quality of life of a person taking, say, cancer drugs, is measured from patients in a clinical trial. These can be translated For NICE assessments, research teams then combine the quantity of life that a treatment buys, with the quality of that time into the Quality Adjusted Life Year (QALY), a measure widely used by health economists. This is calculated by multiplying the utility value of a health state by the length of time spent in that state. One year spent in perfect health, for example, gives a QALY of one. Three years spent in a health state with a utility value of 0.5 equals 1.5 QALYs, equivalent to 1.5 years of perfect health.
Complex calculations
For most conditions, working out the QALY is more than a back-of-the-envelope calculation. Clinical trial results cover only the relatively short span of the trial, but researchers are trying to extrapolate from this a QALY for the rest of a patient's life, during which their health may change. For this they turn to mathematical models into which they put all the information on the effectiveness of the drugs from the literature search, the changes the treatments are likely to make to patients' quality of life, how the disease progresses and the timescales involved.
And the answer? The model developed by Thomson Coon's assessment team showed that treating renal-cell carcinoma with interferon-α gives 1.19 QALYs to the average patient. Adding one of the new drugs, bevacizumab, to interferon-α increased this to 1.45 QALYs. Sunitinib was even better, producing 1.62 QALYs. If money were no object, then sunitinib would be the obvious choice.
But for the NHS, money is crucial -and when cost was added the outcome was much less clear-cut. A course of treatment with interferon-α alone cost £8,438 (US$13,786) at the time of the assessment, whereas one with sunitinib was £39,623. This means the additional 0.44 QALYs -effectively just over five extra months of healthy life -costs an extra £31,185. NICE typically calculates the difference as the cost per QALY, which was £71,462 for sunitinib and £171,301 for interferon with bevacizumab.
How well the QALY system actually reflects patient preferences is still debated. Stephen Birch, a health economist at McMaster University in Ontario, Canada, says that it fails at this most fundamental of levels. A key problem, as Birch sees it, is the assumption built into calculation of QALYs that it is possible to separate time and health. "These two things are not separable, " he says. A person who has been sick for a long time might rate their quality of life differently to someone who has only just become sick. "The QALY doesn't have that, " Birch says.
Despite these criticisms and others, many health economists consider the QALY to be the best option available in comparative-effectiveness research. "The argument at a theoretical level is whether the QALY is a good measure of utility or whether it's a crude measure of length and quality of life that doesn't bear close relationships to people's satisfaction," says Alan Maynard, a health economist at the University of York. "It's not strongly theoretically based. It's pragmatic best practice. That's where we're at. " Once calculated, the QALYs and their costs are returned by the assessment team to NICE, where a separate appraisal committee composed of researchers, medical practitioners and laypeople decide what to do with it. The committee produces a draft decision -called an appraisal consultation document -before accepting comments from interested parties and then releasing a final decision.
Generally anything coming in with a cost per QALY gained of under £30,000 is approved for use -and none of the four renal cancer drugs came even close. More than 80% of drugs are approved for use in some form, however (see  table) . The £30,000 threshold has been criticized for being somewhat arbitrary, but health economists say that it is broadly in line with other spending decisions taken in the NHS, such as those made by health authorities in the absence of NICE guidance. "You can argue that NICE is too generous, " says Maynard. "It probably puts too many things on to the approved list for the NHS, but it's a system that is explicit. " Many health economists think that every country will eventually need some kind of NICE. But the decisions made by the institute are easier to implement in countries that have finite spending on health, such as through a national health service, and therefore a clear basis on which to accept or reject treatments as being affordable or too costly.
The United States has no such limit on health-care spending. The nation's Food and Drug Administration approves a treatment for use if it is deemed to be both safe and effective for the licensed condition -cost is not a factor. The United States did set aside $1.1 billion for comparativeeffectiveness research in its economic stimulus package earlier this year. Policy-makers have not yet worked out whether or how to incorporate such research into decisions on cost. "Our job is the research," says Carolyn Clancy, director of the US Agency for Healthcare Research and Quality, the US body that researches healthcare quality. "The policy-makers are going to have to struggle with 'how is this research applied'."
"We have had quite a lot of dialogue with the current American administration," Rawlins says. He is unsure how far the United States will go down the clinical and cost-effectiveness road, but he agrees with a view that seems widespread among health economists. US citizens "don't get their money's worth and they can't afford it any longer. They can't go on as they are," he says.
Maynard argues that "the American health-care system rations on the basis of whether people have private insurance or not. Forty-six million people haven't got insurance." He adds that private health insurers ought to adopt assessments of clinical and cost effectiveness to make more rational decisions about what to pay for. "Private insurers are poor purchasers of health care because they don't use healthtechnology assessment to ration what they put in their benefit package," he says.
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